Ticker

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced the closing of its initial public offering.

Kardigan's shares ​rose ‌1.6% in their ​Nasdaq ​debut on ⁠Thursday, ​after ​the heart drug developer ​raised $400 ​million in ‌an ⁠upsized U.S. initial public ​offering.

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price…

Kardigan is targeting a valuation of ​up to $1.4 billion in its ‌initial public offering in the United States, the drug developer ​said on Thursday.

Kardigan, Inc. (KARD) is a clinical-stage biopharma targeting various cardiovascular disease treatments with a pipeline led by Danicamtiv, now in Phase 2b/3 trials. KARD leverages its Prolario AI platform to optimize clinical trial design, patient identification, and data collection, aiming for improved outcomes and efficiency. The company is well-capitalized with $287 million in cash and strong backing from…